Since thiosemicarbazones alone have been shown to target PI3K/AKT and MAPK signaling in carcinoma cells (Dixon et al., 2013; Kovacevic et al., 2013, 2016; Lui et al., 2015a; Menezes et al., 2017; Macsek et al., 2022), we assessed the expression and phosphorylation of AKT (Ser473), ERK1/2 (Thr202/204), and MEK1/2 (Ser201/221) after combined treatments of neuroblastoma cells (Figure 7). This evidence concerns the gene MAPK3 and carcinoma.